Document is current

Article History

Received: 4 May 2026

Accepted: 10 June 2026

First Online: 10 July 2026

Declarations

:

: T.We. reports receiving travel and accommodation support from Gilead Sciences and Shionogi Seiyaku, unrelated to the submitted work. P.K. received honoraria from Gilead, Abbvie, ViiV, Camurus, Roche, and Sanofi, all unrelated to the submitted work. A.H. has received honoraria for scientific lectures and sponsored contributions to medical conferences from Gilead Sciences, MSD, and ViiV Healthcare; additionally, she has received travel support and conference registration fees from Gilead Sciences, as well as honoraria for participation in scientific advisory boards from Gilead Sciences and MSD. G.S. reports that all potential conflicts of interest are unrelated to the submitted work. G.S. has received funding from Gilead Sciences and honoraria from ViiV Healthcare, Gilead Sciences, Bristol Myers Squibb, MSD, and Hormosan for advisory board participation, data safety and monitoring board service, development of educational materials, and lectures. G.S. has also received support for meeting attendance and travel from ViiV Healthcare, Gilead Sciences, Bristol Myers Squibb, and MSD. S.B. received received payments for scientific advice from Pfizer, unrelated to the submitted work. C.S. received payments for lectures/scientific advice from the following pharmaceutical companies: Gilead Sciences, Janssen-Cilag, MSD Sharp & Dohme, Shionogi, Theratechnologies and ViiV Healthcare, and travel grants for scientific conferences from AbbVie, Gilead Sciences, MSD Sharp & Dohme and Janssen-Cilag. S.P., M.B., T.Wo., B.M. and T.Wi. have nothing to disclose.